NEW YORK (GenomeWeb News) – Fluidigm today announced its collaboration with Novartis to develop a non-invasive fetal diagnostic test has ended.

The collaboration ended on May 1, when Novartis chose not to exercise an option to exclusively license Fluidigm's digital PCR technology. Fluidgm added that it successfully achieved all of its technical feasibility milestones in the first phase of the collaboration and received all milestone payments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.